Posted: 20 October 2021
Research Australia, Medicines Australia, the Medical Technology Association of Australia (MTAA) and AusBiotech have responded to the HERC IP Framework Consultation paper.
Together, they represent a significant proportion of the health R&D sector and consider it positive that the Department has identified barriers to negotiating and executing commercialisation agreements between universities and business.
However, while they believe the development of a standard IP Framework could be of great assistance to all parties in reaching agreement on commercialisation arrangements, this is an incredibly complex area that requires careful and in-depth consultation.
Apart from the need to conduct an in-depth consultation, the major issue of concern with the Framework relates to the proposal to make use of the IP Framework mandatory in many circumstances.
